The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

Míreanna Comhchosúla

• The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
  le: Wu, Shang-Gin, et al.
  Foilsithe: (2016)
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  le: Shang-Gin Wu, et al.
  Foilsithe: (2017-07-01)
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  le: Wu, Shang-Gin, et al.
  Foilsithe: (2017)
• The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
  le: Wu, Shang-Gin, et al.
  Foilsithe: (2020)
• Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
  le: Gow, Chien-Hung, et al.
  Foilsithe: (2005)